Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy

CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions

(2018) Masao Hashimoto et al.   Annual Review of Medicine

Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy

(2018) Minan Wang et al.   FASEB JOURNAL

Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy

(2018) Yue Zhao et al.   GUT

Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy

(2017) Song Xue et al.   Journal of Hematology & Oncology

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

(2017) Si-Yang Liu et al.   Journal of Hematology & Oncology

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

Current status and perspectives of patient-derived xenograft models in cancer research

(2017) Yunxin Lai et al.   Journal of Hematology & Oncology

Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research

(2017) Tsutomu Kawaguchi et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Raising the bar on first-line immunotherapy in lung cancer

(2017) Jessica J Lin et al.   LANCET ONCOLOGY

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model

(2017) Henrik Jespersen et al.   Nature Communications

CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression

(2017) Shouheng Lin et al.   Frontiers in Immunology

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

(2017) Xinru Wei et al.   OncoImmunology

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib

(2016) E. Larkins et al.   CLINICAL CANCER RESEARCH

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

(2016) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging therapeutic agents for lung cancer

(2016) Bhagirathbhai Dholaria et al.   Journal of Hematology & Oncology

New and emerging targeted treatments in advanced non-small-cell lung cancer

(2016) Fred R Hirsch et al.   LANCET

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer

(2016) Kazuhiko Shien et al.   LUNG CANCER

Correction for Lee et al., Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice

(2016)   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model

(2016) Shi-Dong Ma et al.   PLoS Pathogens

Lung cancer in 2016: immunotherapy comes of age

(2016) Paul L R Mitchell et al.   Lancet Respiratory Medicine

Association ofBIMDeletion Polymorphism With Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Adenocarcinoma

(2016) Shang-Gin Wu et al.   JAMA Oncology

Treatment ofEGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors

(2016) Zofia Piotrowska et al.   JAMA Oncology

Establishment of a Novel Bladder Cancer Xenograft Model in Humanized Immunodeficient Mice

(2015) Zhen Gong et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments

(2015) Wei Ye et al.   Journal of Hematology & Oncology

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

(2015) Yu Fujita et al.   MOLECULAR THERAPY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of non-coding RNA expression from the DLK1-DIO3 imprinted locus correlates with reduced neural differentiation potential in human embryonic stem cell lines

(2015) Chu-Fan Mo et al.   Stem Cell Research & Therapy

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Immune Humanization of Immunodeficient Mice Using Diagnostic Bone Marrow Aspirates from Carcinoma Patients

(2014) Melanie Werner-Klein et al.   PLoS One

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Humanized NOD-SCID IL2rg –/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies

(2013) Qianjun Zhou et al.   CANCER LETTERS

Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models

(2013) D. Siolas et al.   CANCER RESEARCH

Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer

(2013) Hyun Seok Kim et al.   CELL

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

(2013) Thomas F Gajewski et al.   CURRENT OPINION IN IMMUNOLOGY

New cast for a new era: preclinical cancer drug development revisited

(2013) Grit S. Herter-Sprie et al.   JOURNAL OF CLINICAL INVESTIGATION

SnapShot: Lung Cancer Models

(2012) Anna F. Farago et al.   CELL

Human mesenchymal stem cells suppress donor CD4+T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease

(2012) L. M. Tobin et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Adoptive Transfer With In Vitro Expanded Human Regulatory T Cells Protects Against Porcine Islet Xenograft Rejection via Interleukin-10 in Humanized Mice

(2012) Shounan Yi et al.   DIABETES

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High antigen levels are the cause of T cell exhaustion during chronic viral infection

(2009) S. N. Mueller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective expansion of a subset of exhausted CD8 T cells by  PD-L1 blockade

(2008) S. D. Blackburn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA